» Articles » PMID: 30608949

Glycosaminoglycans from Alzheimer's Disease Hippocampus Have Altered Capacities to Bind and Regulate Growth Factors Activities and to Bind Tau

Overview
Journal PLoS One
Date 2019 Jan 5
PMID 30608949
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Glycosaminoglycans (GAGs), including heparan sulfates and chondroitin sulfates, are major components of the extracellular matrix. Upon interacting with heparin binding growth factors (HBGF), GAGs participate to the maintaintenance of tissue homeostasis and contribute to self-healing. Although several processes regulated by HBGF are altered in Alzheimer's disease, it is unknown whether the brain GAG capacities to bind and regulate the function of HBGF or of other heparin binding proteins, as tau, are modified in this disease. Here, we show that total sulfated GAGs from hippocampus of Alzheimer's disease have altered capacities to bind and potentiate the activities of growth factors including FGF-2, VEGF, and BDNF while their capacity to bind to tau is remarkable increased. Alterations of GAG structures and capacities to interact with and regulate the activity of heparin binding proteins might contribute to impaired tissue homeostasis in the Alzheimer's disease brain.

Citing Articles

Capturing biomarkers associated with Alzheimer disease subtypes using data distribution characteristics.

Smith K, Climer S Front Comput Neurosci. 2024; 18:1388504.

PMID: 39309755 PMC: 11413970. DOI: 10.3389/fncom.2024.1388504.


Novel Insights into Changes in Gene Expression within the Hypothalamus in Two Asthma Mouse Models: A Transcriptomic Lung-Brain Axis Study.

Bastawy E, Eraslan I, Voglsanger L, Suphioglu C, Walker A, Dean O Int J Mol Sci. 2024; 25(13).

PMID: 39000495 PMC: 11242700. DOI: 10.3390/ijms25137391.


FGFR3 drives Aβ-induced tau uptake.

Kim D, Suh K, Park J, Lee S, Han J, Chang S Exp Mol Med. 2024; 56(7):1631-1642.

PMID: 38951140 PMC: 11297141. DOI: 10.1038/s12276-024-01274-3.


Vascular Heparan Sulfate and Amyloid-β in Alzheimer's Disease Patients.

McMillan I, Gearing M, Wang L Int J Mol Sci. 2024; 25(7).

PMID: 38612775 PMC: 11012074. DOI: 10.3390/ijms25073964.


Global impact of proteoglycan science on human diseases.

Xie C, Schaefer L, Iozzo R iScience. 2023; 26(11):108095.

PMID: 37867945 PMC: 10589900. DOI: 10.1016/j.isci.2023.108095.


References
1.
Snow A, Sekiguchi R, Nochlin D, Kalaria R, Kimata K . Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. Am J Pathol. 1994; 144(2):337-47. PMC: 1887140. View

2.
Schindowski K, Belarbi K, Buee L . Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav. 2008; 7 Suppl 1:43-56. PMC: 2228393. DOI: 10.1111/j.1601-183X.2007.00378.x. View

3.
Holmes B, DeVos S, Kfoury N, Li M, Jacks R, Yanamandra K . Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S A. 2013; 110(33):E3138-47. PMC: 3746848. DOI: 10.1073/pnas.1301440110. View

4.
Barret A, Forestier L, Deslys J, Julien R, Gallet P . Glycosylation-related gene expression in prion diseases: PrPSc accumulation in scrapie infected GT1 cells depends on beta-1,4-linked GalNAc-4-SO4 hyposulfation. J Biol Chem. 2005; 280(11):10516-23. DOI: 10.1074/jbc.M412635200. View

5.
Solerte S, Ferrari E, Cuzzoni G, Locatelli E, Giustina A, Zamboni M . Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulfate. Dement Geriatr Cogn Disord. 2004; 19(1):1-10. DOI: 10.1159/000080963. View